Arena Pharmaceuticals, Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia

Sept. 25, 2007 - Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced positive preliminary results from its Phase 2 clinical trial of APD125 in patients with chronic insomnia. APD125 is an orally available drug candidate discovered by Arena that is being evaluated in insomnia patients who have difficulty maintaining sleep after initial sleep onset... Arena's Press Release -

Orphan Drug Status to Immtech's Pafuramidine for Treatment of African Sleeping Sickness

Sept. 19, 2007- Immtech Pharmaceuticals, Inc. (Amex: IMM) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to pafuramidine (DB289) for treating Human African Trypanosomiasis (HAT), also known as African sleeping sickness... Immtech Pharmaceuticals' Press Release [PDF] -

Efficacy and Benefit of Restore Medical's Pillar(R) Procedure

Sept. 18, 2007--Restore Medical, Inc. (NASDAQ:REST), developer of the innovative Pillar(R) Palatal Implant System - a simple, minimally-invasive treatment to help individuals suffering from snoring and mild-to-moderate obstructive sleep apnea (OSA) - today announced the presentation of positive results from the first U.S. multi-center Level 1 evidence based medicine clinical study of its Pillar palatal implants, which affirmed the efficacy observed in earlier studies in the treatment of mild to moderate OSA... Restore Medica's Press Procedure -

Neurogen , Webcast of Insomnia Focus

Sept. 18, 2007--Neurogen Corporation (Nasdaq: NRGN), a drug discovery and development company, announced the webcast of its Insomnia Focus Investor meeting on September 25, 2007, from 11:45 a.m. to 2:00 p.m. ET.

Neurogen and guest speakers will take an in-depth look at insomnia therapeutics on the market and in development, and the role of NRGN's adipiplon (formerly NG2-73) in this changing marketplace. Guest speakers are... Neurogen's Press Release -

Cephalon, PROVIGIL Label Updates

Sept. 17, 2007 - Cephalon, Inc. (Nasdaq: CEPH) announced that it has finalized and shared with healthcare professionals revisions to the label for PROVIGIL(R) (modafinil) Tablets [C-IV], its wake-promoting agent... PROVIGIL and NUVIGIL each are indicated to improve wakefulness in adults with excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), shift work sleep disorder and narcolepsy... Cephalon's Press Release -

Restore Medical, Clinical Study to Evaluate Pillar Palatal Implants in Combination with Continuous Positive Airway Pressure

Sept. 17, 2007--Restore Medical, Inc. (NASDAQ:REST), developer of the innovative Pillar(R) Palatal Implant System - a simple, minimally-invasive treatment to help individuals suffering from snoring and mild-to-moderate obstructive sleep apnea (OSA) - announced enrollment of the first patients in a clinical study evaluating the use of Pillar palatal implants in combination with continuous positive airway pressure (CPAP) therapy in the treatment of mild to moderate OSA... Restore Medical's Press Release -

SleePosition, blog about sleep disorders and treatments

The aim of the Blog "SleePosition" is to share information found in life sciences companies websites which could be interesting to follow new medical devices, pharmaceuticals, treatments, clinical trials for sleep disorders.